Table 1 Overview of guidelines included in the study and characteristics of the development process
Guidelines a (country or organisation and year of publication) | Time (years) between current and previous version | Date for planned revision presented | Comprehensible description of literature search | GPs/all members in development committees (n) | Separate recommendations for inpatients and outpatients | Funding by the pharmaceutical industry |
|---|---|---|---|---|---|---|
Austria61 2004 | 15 | No | No | NA | No | NA |
IPCRG62 2006 | NA | No | No | 4/8 | For primary care | Yes |
Denmark63 2007 | NA | No | No | 1/20 | Yes | NA |
Netherlands64 2007 | 6 | No | No | 7/9 | For primary care | No |
Sweden65 2009 | NA | No | No | 2/8 | Yes | NA |
Germany66 2009 | 4 | Yes | No | 0/14 | No | No |
NICE67 2010 | 6 | No | Yes | 4/31 | Yes | No |
South Africa68 2011 | 2 | No | Yes | NA | No | Yes |
Canada69 2011 | NA | No | No | NA | No | NA |
ERS70 2011 | 6 | No | Yes | 1/12 | Yes | No |
Australia/New Zealand71 2012 | 9 | No | No | 3/45 | No | Yes |
Norway72 2012 | NA | No | No | 2/8 | Yes | NA |
Switzerland73 2013 | 10 | No | No | 1/13 | Yes | NA |
ICSI74 2013 | 1 | Yes | Yes | 0/10 | No | No |
GOLD75 2013 | 1 | Yes | Yes | 2/25 | No | Yes |
Cont. | Yes | No | NA | No | NA | |
India78 2013 | NA | No | Yes | NA | No | NA |
Saudi79 2014 | NA | No | Yes | 0/12 | Yes | No |
Spain46 2014 | 4 | No | No | 0/19 | Yes | Yes |
